Giuliana Grossi

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

According to the data, sleep quality, fatigue, and social well-being contribute to depression among young adults with autism, with social well-being being a significant predictor of depression over a 2-year period.

The new analysis on the screening tool in primary care patients with COPD highlights the need for further research to optimize CAPTURE's performance and impact on clinical outcomes.

Once-weekly efanesoctocog alfa is a safe and effective treatment for patients with severe hemophilia A, providing better outcomes than current treatment options by significantly reducing bleeding rates and improving physical health, pain, and joint health.

Frailty is a serious issue in hospitalized patients and is associated with increased morbidity and mortality. However, a recent study suggests that the Hospital Frailty Risk Score (HFRS), may not be effective in identifying frailty in hospitalized COPD patients compared to the bedside Clinical Frailty Scale (CFS).

Dr. Matthew Lander explains that the number of cardiac sarcoidosis cases might be lower than other forms of sarcoidosis, but the outcomes are more severe.

The analysis uses patient data from SPIROMICS, followed by an external validation with the results from COPDGene.

According to older literature, most cases of sarcoidosis involve the lungs, but Dr. Matthew Lander explains why there could be more to the rare disease.

Findings demonstrated a significant association between having an asthma management plan and use of inhaled or oral medicine, independent of country income and asthma severity.

More than 98,000 medical device reports have been sent to the FDA since April 2021 regarding Philips Respironics Ventilators, BiPAP, and CPAP machines associated with the PE-PUR foam breakdown.

PET scanning, in particular, has provided advancement in the diagnosis process, which has offered a new perspective on cardiac sarcoidosis for clinicians.

According to the results, 42.8% of participants failed to agree that relevant legislature is in place for the sickle cell disease population, as it doesn't facilitate optimal access to high-quality healthcare.

Patients with with depression and AHI ≥ 30 show the greatest risk of all-cause mortality.

The positivity rate of rhinoviruses and enteroviruses decreased briefly following the onset of the COVID-19 pandemic, but by fall of 2020 resumed almost to pre-pandemic levels.

It wasn't the unavailability of varenicline, but the inaccessibility, that perpetuated the reduced prevalence of prescriptions. Investigators speculated that patient, clinician awareness and concerns related to nitrosamine were contributing factors.

The rare condition can lead to life-threatening anemia in the fetus and currently lacks FDA-approved treatments.

The Sickle Cell Trait Awareness Campaign (STAC) offers promising possibilities of expanding sickle cell trait education across the country, Dr. Carolyn Rowley and Pat Corley, RN explain.

Individuals with sickle cell trait not only need to know their status to make informed family planning decisions, but also so they can watch out for the possible symptoms.

The mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) showed no risk of Guillain-Barré syndrome post-vaccination.

Dr. Carolyn Rowley explains, the whole reason for the Sickle Cell Trait Awareness Campaign (STAC) is to start talking about it.

"Despite advances in SCD management and high-risk pregnancy care, at the national level, outcomes in this population have not improved since the last NIS analysis of data from 1999 to 2008," investigators write.

Dr. Carolyn Rowley and Pat Corley, RN, explain why the new Sickle Cell Trait Awareness Campaign is designed for all middle school, high school, and university students.

In an effort to address unmet needs related to the accessibility of biosimilars globally, the WHO updates the guidelines to include more therapies in the category.

Natalizumab PB006 is the first biosimilar monoclonal antibody developed for treating patients with multiple sclerosis (MS).

Dr. Ian Flinn says many patients opt for treatment with Bruton's tyrosine kinase (BTK) over combination therapy.

The specific mechanisms involved in associations between air pollution and respiratory illness without viral infection are not understood, especially compared with those of respiratory viruses and asthma exacerbation.

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

The study population consists of patients who received 1-3 prior lines of therapy for relapsed and lenalidomide-refractory multiple myeloma.

The monoclonal antibody serves as the first and only therapy for treating hemolysis in adults with cold agglutinin disease, an extremely rare condition.

“Repurposing approved drugs developed for other conditions presents an attractive strategy to identify new treatment options and expand access to potentially lifesaving care,” investigators wrote.